Increased macrophage infection upon subcutaneous inoculation of rhesus macaques with simian immunodeficiency virus-loaded dendritic cells or T cells but not with cell-free virus by Ignatius, Ralf et al.
Rockefeller University 
Digital Commons @ RU 
Publications Steinman Laboratory Archive 
2002 
Increased macrophage infection upon subcutaneous inoculation 
of rhesus macaques with simian immunodeficiency virus-loaded 




Follow this and additional works at: https://digitalcommons.rockefeller.edu/steinman-publications 
Recommended Citation 
Ignatius, R., K. Tenner-Racz, D. Messmer, A. Gettie, J. Blanchard, A. Luckay, C. Russo, et al. 2002. 
"Increased Macrophage Infection upon Subcutaneous Inoculation of Rhesus Macaques with Simian 
Immunodeficiency Virus-Loaded Dendritic Cells Or T Cells but Not with Cell-Free Virus." Journal of 
Virology 76 (19): 9787-9797 
This Article is brought to you for free and open access by the Steinman Laboratory Archive at Digital Commons @ 
RU. It has been accepted for inclusion in Publications by an authorized administrator of Digital Commons @ RU. 
For more information, please contact nilovao@rockefeller.edu. 
JOURNAL OF VIROLOGY, Oct. 2002, p. 9787–9797 Vol. 76, No. 19
0022-538X/02/$04.000 DOI: 10.1128/JVI.76.19.9787–9797.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Increased Macrophage Infection upon Subcutaneous Inoculation of
Rhesus Macaques with Simian Immunodeficiency Virus-Loaded
Dendritic Cells or T Cells but Not with Cell-Free Virus
Ralf Ignatius,1† Klara Tenner-Racz,2 Davorka Messmer,1‡ Agegnehu Gettie,3 James Blanchard,4
Amara Luckay,3 Christine Russo,3 Stephen Smith,5 Preston A. Marx,3,4 Ralph M. Steinman,1
Paul Racz,2and Melissa Pope1*
Laboratory of Cellular Physiology and Immunology, The Rockefeller University, New York, New York 100211; Bernhard
Nocht Institute for Tropical Medicine, 20359 Hamburg, Germany2; The Aaron Diamond AIDS Research Center,
The Rockefeller University, New York, New York 100163; Tulane Regional Primate Research Center, Covington,
Louisiana 704334; and St. Michael’s Medical Center and The New Jersey Medical School,
Newark, New Jersey 071025
Received 3 April 2002/Accepted 18 June 2002
Information on the establishment of immunodeficiency virus infection through transmission of infected cells
is sparse. Dendritic cells (DCs) and T cells may be central to the onset and subsequent spread of infection
following mucosal exposure. To directly investigate the consequences of virus being introduced by DCs or T
cells, we reinjected ex vivo simian immunodeficiency virus (SIV)-loaded autologous immature DCs and T cells
subcutaneously (s.c.) into healthy macaques. s.c. injection of cell-bound virus was used to mirror what may
happen if virus-loaded cells pass through an epithelium or perhaps DCs and T cells that immediately entrap
cell-free virus, having just crossed an epithelial barrier. Virus load in the plasma was monitored along with
combined in situ hybridization and immunohistochemistry to identify the cells replicating virus in the lym-
phoid tissues. Both DCs and T cells transmitted infection after being pulsed with either wild-type or nef-
defective (delta nef) SIVmac239. As seen in animals infected intravenously, replication of delta nef was
attenuated compared to that of wild-type virus when introduced in either cell-bound form. Upon examination
of the draining lymph nodes (LNs) during the first days of infection, virus-producing CD4 T cells predom-
inated in control animals that received s.c. cell-free virus. In dramatic contrast, both SIV-positive macrophages
and T cells were detected in the LNs of monkeys infected with cell-associated SIV. Therefore, although both
cell-free and cell-associated viruses are infectious, the initial cells amplifying the virus differ. This may have
important implications for the subsequent dissemination of infection and/or induction of antiretroviral
immunity.
Transmission of immunodeficiency viruses (human immuno-
deficiency virus type 1 [HIV-1] and simian immunodeficiency
virus [SIV]) can occur either by free virus or by transmission of
infected host cells. Dendritic cells (DCs) and T cells are among
the most important cells that are able to capture immunode-
ficiency viruses and promote their replication (13, 22). Physi-
ologically, DCs in an immature state capture foreign particles
at the skin and mucosae and traffic them to the draining lymph
nodes (LNs), where the matured DCs would induce effective
antigen (Ag)-specific T- and B-cell-mediated immune re-
sponses (3). Considerable evidence exists from human and
macaque studies for the ability of these sentinel cells to drive
virus replication in vitro and in vivo (13, 22).
In vivo, within 2 to 3 days following application of SIV to the
tonsillar (46, 47) or vaginal (52) mucosae, CD4 T cells were
identified as the major site of SIV RNA expression. However,
Hu et al. (16) reported that DCs within the outer epithelium,
Langerhans cells, were the first cells that were found to express
SIV RNA, being detected within 18 h after vaginal exposure of
macaques to the virus. These findings support a longstanding
hypothesis that DCs are one of the first cells encountering
viruses that breach the mucosae and then very efficiently prop-
agate virus spread, particularly upon interaction with CD4 T
cells first locally and then in the draining lymphoid tissues.
In vitro, immature CCR5 DCs can replicate R5 HIV-1
isolates (14), whereas mature CCR5/low, CXCR4 DCs are
able to promote the extensive amplification of R5 and X4
HIV-1 as long as CD4 T cells are present but support limited
replication in the absence of T cells (reviewed in references 13
and 22). Similarly, SIV replicates well in autologous DC–T-cell
mixtures from macaque blood, skin, and mucosal sites (20, 34,
40). Either virus-loaded DCs or T cells introduce infectious
virus to the DC–T-cell mixtures, and virus growth requires no
additional external stimulus. The T cells do not need to enter
the cell cycle for the virus to amplify (39, 41), much like what
has been observed in vivo (45, 48, 49). Virus replication in the
immature DC–T-cell milieu has also been shown to be depen-
dent on the presence of nef (34, 38). However, mature DCs
promote replication of wild-type virus and an attenuated ver-
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sion of the virus with a deletion in the nef gene (delta nef) (34).
This directly reflects the attenuated growth of the virus in vivo
(23, 43), which mimics the prolonged survival of a cohort of
HIV-infected individuals who exhibit minimal immune de-
struction after being infected for many years with nef-defective
virus (8, 24, 27, 28). This also provides a primary cell system
that is representative of the cellular locale encountered by the
virus as it crosses the mucosae (22). Therefore, both cellular
and viral components influence the level of replication in the
DC–T-cell milieu.
This study set out to investigate whether wild-type versus
delta nef SIV could be transmitted by virus-loaded immature
DCs or CD4 T cells in vivo and to determine what cell types
are responsible for the early virus replication in this setting.
We exposed immature DCs or CD4 T cells to wild-type or
delta nef virus in vitro, before subcutaneously (s.c.) reinjecting
the virus-carrying cells into the donor animal. This strategy
aimed at approximating the events following the DC or T-cell
capture of virus that has just breached an epithelial barrier or
the scenario that such virus-carrying cells traversed the epithe-
lia. All animals became infected after injection of cell-associ-
ated virus s.c. or of cell-free virus s.c. or intravenously (i.v.).
Delta nef virus-infected animals exhibited lower viremia, and
fewer virus-positive cells were detected in the lymphoid tissues.
Strikingly, there was a considerable increase in the involve-
ment of macrophages in the early replication and spread of
infection with cell-associated virus, unlike the almost exclusive
virus-producing CD4 T cells detected after injection of cell-
free virus. This suggests that the initial mode of virus dissem-
ination differs for cell-free versus cell-associated virus and may
influence the design of strategies aimed at preventing infec-
tion.
MATERIALS AND METHODS
Culture medium and cytokines. RPMI 1640 (Cellgro; Fisher Scientific, Spring-
field, N.J.) containing 10 mM HEPES (GIBCO-BRL, Life Technologies, Grand
Island, N.Y.), 2 mM L-glutamine (GIBCO-BRL), 50 M 2-mercaptoethanol
(Sigma Chemical Company, St. Louis, Mo.), penicillin (100 U/ml)-streptomycin
(100 g/ml) (GIBCO-BRL), and 1% heparinized human plasma was used
throughout these studies. 174xCEM cells (obtained from the NIH AIDS Re-
search and Reference Reagent Program) were maintained in culture medium
containing 10% fetal calf serum (Sigma).
Animals. Prior to use, the adult male and female rhesus macaques (Macaca
mulatta) used for this study were confirmed to be negative for antibodies (Abs)
to SIV, type D retroviruses, and simian T-cell leukemia virus type 1. The ma-
caques were housed at the Tulane Regional Primate Research Center. Animal
care operations in compliance with the regulations detailed under the Animal
Welfare Act, and in the Guide for the Care and Use of Laboratory Animals were
observed. Animals were anesthetized with ketamine-HCl (10 mg/kg) prior to all
procedures. Intravenous inoculation was achieved by injecting 102 50% tissue
culture infectious doses (TCID50) of wild-type SIVmac239 or 2.35  104 TCID50
of delta nef virus as per an established protocol (7). As indicated, animals were
injected with autologous cell-associated virus (see below) s.c. at three sites (total
of 0.5 ml) approximately 1 to 2 cm from palpated LNs of the inguinal or axillar
regions. Control animals received 102 or 105 TCID50 of cell-free wild-type or
delta nef virus injected s.c at three sites proximal to an inguinal LN. Skin punch
biopsies and LN samples were aseptically taken from the injection site at 1, 3, 7,
and 14 days postinfection (p.i.). Part of each tissue sample was kept frozen or
fixed in formalin for combined immunohistochemistry (IH)-in situ hybridization
(ISH) analysis, while other parts of the tissue were used to prepare single-cell
suspensions (17, 18) to set up in cocultures to detect infectious virus (below).
Generation of DCs and T cells. Monocyte-derived DCs were generated from
adherent monocytes (36). Eighty milliliters of heparinized blood was obtained
from healthy anesthetized animals and the peripheral blood mononuclear cells
(PBMCs) were collected over a Ficoll-Hypaque density gradient (Pharmacia,
Uppsala, Sweden). A total of 1.2  107 to 1.5  107 PBMCs were plated per well
of a six-well plate (Becton Dickinson Labware, Franklin Lakes, N.J.) and incu-
bated for 1 to 2 h at 37°C. After removal of nonadherent cells, fresh culture
medium containing 1000 U of recombinant human granulocyte-macrophage
colony-stimulating factor (Immunex, Seattle, Wash.) per ml and 100 U of re-
combinant human interleukin-4 (R&D Systems, Minneapolis, Minn.) per ml was
added. Cytokines were replenished every other day by replacing 0.3 ml of me-
dium with 0.5 ml of medium with additional cytokines. After 7 days, immature
DCs were collected and contaminating CD2 T and CD20 B cells were de-
pleted by using three rounds of magnetic Dynabeads (Dynal, Oslo, Norway) (34).
CD4 T-cell-enriched fractions were obtained from PBMCs isolated from 80
ml of heparinized blood samples by removing the HLA-DR and CD8 subsets
with Dynabeads (34). PBMCs were stained with a mouse anti-human CD8
monoclonal Ab (MAb) (Becton Dickinson Immunocytometery Systems [BDIS],
San Jose, Calif.), washed, and mixed with goat anti-mouse immunoglobulin
(Ig)-coated beads as well as an equal amount of anti-HLA-DR-coated beads.
The cell-bead mixtures were incubated with rotation for 20 min at 4°C. This was
repeated twice more upon addition of fresh beads.
The phenotype and purity of DCs and T cells were monitored by flow cytom-
etry using a FACScan flow cytometer (Becton Dickinson, Mountain View, Calif.)
and analyzed with Cell Quest Software. DCs were analyzed by using fluorescein
isothiocyanate-conjugated anti-HLA-DR (BDIS) combined with phycoerythrin-
conjugated IgG; anti-CD2 (Dako, Carpinteria, Calif.); anti-CD20, -CD25, and
-CD80 (BDIS); anti-CD83 (Coulter Corp, Miami, Fla.); or anti-CD86 (PharM-
ingen, San Diego, Calif.). T cells were evaluated by using MAbs against CD4
(Ortho, Raritan, N.J.), CD8, HLA-DR, and CD2.
In vitro loading of DCs and T cells with virus. Purified DCs and CD4 T cells
(a maximum of 106 cells per 1.5-ml Eppendorf tube in 500 l of medium) were
exposed to SIVmac239 or delta nef SIVmac239 at a multiplicity of infection
(MOI) of 0.1. After 1.5 h at 37°C the cells were washed four times with 0.5 to 1
ml of cold medium by using an Eppendorf centrifuge (five spins at 2,500 rpm for
2 to 3 min) to remove unbound virus (12, 41), counted (by trypan blue exclusion),
and placed back into culture overnight. Immature DCs were kept in medium
containing granulocyte-macrophage colony-stimulating factor and interleukin-4.
The following morning, the cells were collected and washed four times again, and
the counted cells were pelleted in cold medium. We have shown previously that
this extensive washing procedure efficiently removes the bulk (if not all) of the
cell-free virus (as determined by quantitative reverse transcription-PCR analysis
of the supernatant washes for viral gag RNA) (12). Subjecting the cells to another
round of this washing procedure after the overnight cultures further reduced the
likelihood of any cell-free virus carryover. The cells were kept on ice before being
injected within the next 6 h. Before reinjection, the tubes were recentrifuged one
more time and the cells were resuspended in 1 ml of RPMI and transferred to a
2-ml syringe. In the initial studies, the DCs from two animals (F154 and L780)
were pulsed with SIVmac239 (MOI of 0.1) and then cultured overnight in the
presence of 10 g of tetanus toxoid (TT) (Staten Seruminstitut, Copenhagen,
Denmark) per ml.
Aliquots of the virus-pulsed cells were cocultured with the SIV-permissive
174xCEM cell line to verify the presence of transmissible virus, as described
previously (22). In brief, virus-loaded cells were mixed with the 174xCEM cells
(104 virus-carrying cells per 105 174xCEM cells), and virus replication was mon-
itored over the next days by measuring reverse transcriptase (RTase) activity (5).
Where possible, additional aliquots of virus-pulsed cells were cultured alone (105
cells per well) or in the presence of 174xCEM cells (104 virus-carrying cells per
105 174xCEM cells) for 2 days before SIV gag DNA levels were monitored by
PCR (see below). When cell numbers permitted, samples of virus-loaded cells
were analyzed directly by PCR to monitor viral DNA loads.
IH and ISH. IH was performed prior to ISH. To unmask Ags, dewaxed
paraffin sections (5 m thick) were boiled in 0.01 M buffered sodium citrate
solution (pH 6) for 2 min. Cryostat sections were fixed in 2% paraformaldehyde
for 10 min. The sections were incubated with primary Abs (Table 1) to defined
cellular Ags according to the manufacturers’ instructions. Binding of Abs was
visualized either by the alkaline phosphatase–anti-alkaline phosphatase method
using New fuchsin as the chromogen or by the peroxidase technique. The sec-
tions were either counterstained with hemalaun and mounted or subjected to
ISH.
ISH was performed on either paraffin or cryostat sections as described previ-
ously (42). Briefly, frozen sections were fixed in 4% paraformaldehyde, and
dewaxed paraffin sections were boiled in a domestic pressure cooker in citrate
buffer (pH 6.0) for 5 min prior to hybridization. The sections were hybridized to
a 35S-labeled, single-stranded antisense RNA probe of SIVmac239 (Lofstrand
Labs, Gaithersburg, Md.) overnight at 45°C. As a negative control, sections were
hybridized with a 35S-labeled sense probe. The sections were then dipped into
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photo emulsion (NTB2; Kodak, Rochester, N.Y.), exposed for 3 to 7 days,
developed, counterstained with hemalaun, and mounted. To determine the fre-
quency of SIV RNA-positive cells per square millimeter of section, we used a
microscope (Axiophot; Carl Zeiss Inc., Jena, Germany) equipped with Plan
Neofluar for transmitted and incident light, a 3CD color camera, and a PC-based
image analysis system (KS 400; Kontron, Esching, Germany).
Coculture assays for the detection of infectious virus from infected animals.
Aliquots of PBMCs or LN cells (LNCs) (17, 18) were collected at various times
after infection, and equal numbers of PBMCs or LNCs (2  106 to 5  106) were
cultured with equal numbers of 174xCEM cells in 5 ml of medium in T25 flasks
for up to 3 weeks. When there were fewer than 1.5  106 PBMCs available,
cocultures were set up in 24-well plates. Cultures were split two or three times
per week. Syncytium formation was monitored by microscopy, and virus ampli-
fication was confirmed in culture supernatants at days 14 and 21 by the detection
of p27 Ag with a commercially available enzyme-linked immunosorbent assay
(ELISA) (Zeptometrix, Buffalo, N.Y.) according to the manufacturer’s protocol
(31).
Anti-SIV Ab assays. Plasma samples obtained at the indicated times after
infection were monitored for the presence of SIV envelope Abs by using an
established protocol (44).
Detection of virus protein and RNA in the plasma. Plasma was separated from
heparinized blood samples and stored at 70°C. SIV p27 Ag levels in plasma
were measured by ELISA (Zeptometrix). In addition, the numbers of viral RNA
copies were determined by bDNA analyses with a lower detection limit of 1,500
copies per ml of plasma (Bayer Reference Testing Laboratory, Bayer Diagnos-
tics, Berkley, Calif.) (32).
PCR analysis of SIV gag DNA. Using an established protocol (51), proviral
DNA was detected by PCR with primers detecting late gag sequences (6).
Virus-pulsed cells (105 total) were transferred into a 0.5-ml microcentrifuge tube
(CNO650-GT; National Scientific, San Rafael, Calif.) and centrifuged 2 to 3 min
at 3,000 rpm (MicroSpin 12S; Sorvall Instruments, Dupont), and the cells were
washed once in cold phosphate-buffered saline for 2 to 3 min at 3,000 rpm. The
supernatant was carefully aspirated, and the pellet was resuspended in 50 l of
hypotonic lysis buffer (10 mM Tris [pH 8.0], 1 mM EDTA, 0.001% Triton
X-100–sodium dodecyl sulfate in sterile double-distilled water [ddH2O]) con-
taining 600 g of proteinase K (Boehringer Mannheim, Roche Molecular Bio-
chemicals, Indianapolis, Ind.) per ml. The cells were then incubated for 1 h at
56°C, followed by 15 min at 95°C, to inactivate the protease. After lysis, aliquots
of the DNA were stored at 20°C. To amplify the gag gene sequence, the
primers DSgag1 (plus strand; 5ATG GGC GCG AGA AAC TCC GTC TTG3)
and DBgag5 (minus strand; 5TCC AAC AGG CTT TCT GCT AAT CC3) were
used. DNA (equivalents of 2  104 cells) was added to 50 l of a PCR mixture
containing 20 pmol of each primer, 1 reaction buffer (Promega, Madison,
Wis.), 3 mM MgCl2, 200 M each deoxynucleoside triphosphate (Boehringer
Mannheim), 2 U of Taq DNA polymerase (M1861; Promega) and 4 Ci of
[32P]dCTP (NEG013H; NEN, Boston, Mass.) in ddH2O. Two drops of mineral
oil were added to the samples, and amplification was carried out in a DNA
thermal cycler (Perkin-Elmer Cetus, Norwalk, Conn.). Amplification involved
three cycles of 94°C for 1 min, 56°C for 30 s, and 72°C for 30 s followed by 26
cycles of 95°C for 10 s, 58°C for 30 s, and 72°C for 30 s. PCR products were
separated on an 8% acrylamide gel run in 0.5 Tris-borate-EDTA. Gels were
dried and exposed to XAR-5 film (Kodak, Rochester, N.Y.). For normalization
of the PCR products, the cellular gene for glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was amplified from each sample, using a modified version of
an established PCR protocol (50). In brief, to amplify the GAPDH gene se-
quence, the following primers were used: GAP1 (plus strand; TGG TAT CGT
GGA AGG ACT CAT GGT) and GAP2 (minus strand; GGA AGG AAA TTA
TGG GAA AGC CAG). Fifty microliters of a reaction mix containing 50 pM
each primer, 8 mM MgCl2, 2.5 Ci of [32P]dCTP (NEN), 120 M cold de-
oxynucleoside triphosphates, ddH2O, and 2 U of Taq DNA polymerase was
added to 2 l of each DNA sample (approximately 4  103 cells). Two drops of
mineral oil were added to the samples, and the reaction was carried out in 22
cycles of 1 min at 94°C and 2 min at 67°C. Amplified products were visualized
with an 8% acrylamide gel (see above).
RESULTS
Transmission of infection via s.c. injected SIV-carrying
DCs. SIV-pulsed DCs, while hardly replicating virus them-
selves, are able to transmit virus to T cells in vitro, thereby
initiating robust viral replication (13, 22). To investigate
whether s.c. administered DC-borne virus would transmit in-
fection in vivo, immature DCs were obtained from two healthy
macaques, pulsed with SIVmac239 (MOI of 0.1), washed thor-
oughly to remove cell-free virus, and cultured overnight in the
presence of 10 g of TT per ml. The TT was included in order
to verify that functional DCs had reached the draining LNs,
where they should prime a TT-specific T-cell response, as we
have seen in healthy animals with TT-pulsed, uninfected DCs
(unpublished observations). On the following day, the cells
were collected, washed again, and counted, and 1  106 to 2 
106 autologous DCs were reinjected at three sites proximal to
an inguinal LN. The largest numbers of DCs able to be injected
were used in this pilot experiment.
Aliquots of the virus-loaded cells were able to rapidly am-
plify virus in vitro upon coculture with 174xCEM cells (Fig.
1A), confirming the presence of infectious virus in the cell
preparations used for reinjection. Both animals exhibited sig-
nificant plasma viremia within 2 weeks of the s.c. administra-
tion of the 1  106 to 2  106 virus-carrying DCs, which did not
rebound to lower set point levels (Fig. 1B). With dramatically
increasing viremia, animal F154 had to be euthanized after 73
days due to clinical symptoms suggestive of disease progres-
sion. Autopsy confirmed lesions of immunodeficiency disease,
and high levels of virus (approximately 1010 RNA copies/ml)
were detected in the blood (Fig. 1B) and in the lymphoid
tissues as verified by PCR (estimates of 102 to 103 SIV gag
copies per 105 spleen cells and LNCs, respectively) (Fig. 1C).
F154 was likely a rapid progressor, exhibiting the extremely
high viremia coincident with an elevated plasma SIV p27 Ag
value at week 3 and an absence of a detectable anti-SIV Ab
response (even at necropsy). Subsequently, animal L780 died
within 7 months after developing simian AIDS. However, even
with considerable virus levels and the presence of SIV p27 Ag
in the plasma, L780 did develop an anti-SIV Ab response.
TABLE 1. Antibodies used for immunohistochemistry
Antigen Clone Source Isotype Cells identified
CD3 NAa Dako Rabbit Ig T cells
CD4 Leu3A BD IgG1 T cells, macrophages
NCL-CD4-1F6 Novocastra IgG1 T cells, macrophages
CD68 KP1 Dako IgG1 Macrophages
Sialoadhesin (CD169) 2D7 P. Crocker, University of Dundee IgG1 Macrophages
CD1a SK9 BD IgG2b Langerhans cells
Fascin, p55 55K AIDS Research and Reference
Reagent Program
IgG1 Mature DCs
DC-LAMP (CD208) 104.G4 S. Saeland, Schering Plough IgG1 Mature DCs
a NA, not applicable. Rabbit polyclonal anti-CD3 was visualized by the peroxidase-antiperoxidase method.
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Therefore, s.c. injection of autologous immature DCs that
are carrying wild-type SIV resulted in the rapid and efficient
infection of macaques. In standard T-cell proliferation assays
on PBMCs (10) with the same working batch of TT applied to
separate concurrent in vitro studies (21) as well as to prime
naive macaques, no TT-specific T-cell priming was detected in
these infected animals at several time points after reinjection
of the SIV- and TT-carrying DCs. In each immune assay,
aliquots of the PBMCs were also stimulated with the superan-
tigen SEB to verify that the cells were functional. This is in
contrast to the TT-specific priming seen when DC-borne TT
was used to prime healthy humans (11) and macaques (unpub-
lished observations) in the absence of infection. Assuming that
the reinjected DCs bearing SIV and TT were functional, it is
possible that the T cells responding to the TT provided a
perfect niche in which the wild-type virus rapidly replicated (as
can be seen in vitro [22]), consequently destroying the TT-
responding cells and rendering the animals unprimed to TT.
However, the definitive experiments necessary to address this
issue were not the focus of these studies. In sum, the rapid
infection resulting from the application of virus-carrying DCs
does not correlate with the induction of strong immune re-
sponses to coadministered Ags.
Transmission of wild-type and delta nef infection by DCs
and T cells. Having established the model approach in which 1
 106 to 2  106 DCs loaded with virus in vitro could efficiently
transmit wild-type infection upon s.c. reinjection, we extended
this to examine whether fewer DCs or T cells (3  105) could
transmit both wild-type and delta nef viruses. Based on our
earlier in vitro findings that either DCs or T cells can introduce
infectious virus and that vigorous virus replication required nef
(34), we were especially interested in whether immature DCs
or resting CD4 T cells would be able to transmit delta nef
virus in vivo.
Immature DCs (11 animals) or CD4 T cells (6 animals)
obtained from healthy rhesus macaques were infected with
wild-type virus (DCs from five animals and T cells from four
animals) or delta nef (DCs from six animals and T cells from
two animals) at an MOI of 0.1, washed, and incubated over-
night. The cells were then washed again before being injected
s.c. proximal to the inguinal or axillary LNs of the donor
animals. A minimum of 3  105 cells were injected at each
inguinal or axillary site (Table 2). Six of the animals (two
inoculated with DCs infected with wild-type virus, two inocu-
lated with DCs infected with delta nef virus, and two inoculated
with T cells infected with wild-type virus) (Table 2) were in-
jected s.c. with 3  105 cells at three or four different sites close
to the inguinal and axillary LNs (two inguinal and two axillary
locations and a maximum of 1.2  106 cells per animal).
The presence of infectious virus in each virus-pulsed cell
preparation was verified in vitro by coculturing an aliquot of
the virus-carrying cells with permissive 174xCEM cells and
microscopically monitoring syncytium formation in the cocul-
tures or SIV p27 production by ELISA. When possible, PCR
analysis for SIV gag DNA was performed and revealed that
undetectable or 10 to 100 copies of SIV gag DNA was associ-
ated with 3  105 reinjected cells. Figure 2A shows two exam-
ples (animals P741 [delta nef virus-loaded DCs] and H917
[wild-type virus-loaded DCs]), in which aliquots of the injected
virus-pulsed DCs were cultured alone (105 DCs) or with
174xCEM cells (104 DCs with 105 174xCEM cells) for 2 days to
amplify the virus prior to PCR analysis for SIV gag DNA.
Amplification of the negligible signals seen in the purified DCs
alone is evident after 2 days of coculture of 1/10 of the DCs
with 174xCEM cells (Fig. 2A).
Control animals were infected with s.c or i.v. administered
cell-free virus (Table 2). DC- and T-cell-associated virus likely
comprises fractions of virus that have infected the cells, as well
as virions (potentially infectious) that are bound to the cell
surface or internalized into intracellular compartments (12).
FIG. 1. Immature DCs exposed to SIVmac239 in vitro transmit infection after s.c. reinjection. (A and B) Immature monocyte-derived DCs from
two healthy macaques (F154 and L780) were exposed to SIVmac239 (MOI of 0.1), washed, and cultured overnight in the presence of 10 g of TT
per ml. The next day, the cells were washed again, recounted, and monitored for their ability to transmit infection in vitro (A) and in vivo (B).
(A) Virus-loaded DCs were mixed with 174xCEM cells (104 DCs with 105 174xCEM [CEM] cells [F154 DC-SIVCEM and L780 DC-SIVCEM])
or plated alone (F154 DC-SIV and L780 DC-SIV) and cultured for approximately 2 weeks. Starting at day 3 of culture, supernatants were sampled
every other day and monitored for the presence of RTase activity. The results are expressed as cpm (103) of RTase activity per l of culture
supernatant. (B) SIV and TT-bearing DCs (L780, 2  106 DC-SIV; F154, 1  106 DC-SIV) were s.c. reinjected into the donor animals at three
sites proximal to an inguinal LN. Blood samples collected over the ensuing weeks were analyzed for virus RNA levels by bDNA analysis. The
numbers of RNA copies per milliliter of plasma are shown. (C) LN and spleen (Sp) cell suspensions isolated from tissues obtained at necropsy
of animal F154 were assessed for virus levels by SIV gag PCR. Aliquots of 105 cells were sampled, and the SIV gag DNA was amplified. Standard
curve controls representing 0 (lane ), 101 (lane 1), 102 (lane 2), 103 (lane 3), and 104 (lane 4) SIV gag copies were included to estimate SIV gag
copy numbers in each test sample.
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With an MOI of 0.1 for the cell infections, the maximum
amount of cell-associated virus that could have been injected
with 3  105 cells was 3  104 infectious doses (or 1.2  105 for
animals receiving 1.2  106 cells). While the PCR data suggest
that a maximum of only 100 copies of SIV DNA would be
associated with the injected cells, our recent studies using real
time reverse transcription-PCR for SIV gag RNA also suggest
that an average of 34% of the input virus can be captured by
immature DCs (12), and this gives no indication as to what
proportion of that would be infectious. Consequently, four
animals were injected s.c. with 102 or 105 TCID50 of wild-type
or delta nef virus in an attempt to cover the extreme situa-
tions of viral transmission. Animals receiving wild-type (102
TCID50) or delta nef (2.35  10
4 TCID50) SIV i.v. were also
included as comparative controls of cell-free virus infection
(7).
After injection of cell-free or cell-associated virus, the ani-
mals had regular blood samples taken over the next weeks and
LN samples biopsied at the indicated time points p.i. In the
plasma, Ab responses as well as plasma viremia measurements
(SIV RNA measured by bDNA and SIV Ag levels measured by
ELISA) were determined. Virus was detected in the PBMCs
by PCR, with the virus DNA levels increasing over time (see,
e.g., Fig. 2B, weeks 1, 4, and 6 p.i.), and its infectivity was
confirmed in coculture assays. Each animal became infected
within days of exposure, with plasma p27 Ag being detected
within 1 to 3 weeks p.i. (Table 2) and the peak viremia occur-
ring within 2 weeks p.i. for animals receiving wild-type virus-
infected cells and at 2 to 3 weeks p.i. for those receiving delta
nef virus-infected cells (Fig. 3). Overall, animals injected with
cell-associated wild-type virus showed peak levels of approxi-
mately 2  106 to 6  107 virus copies/ml of plasma, compared
to only 7  104 to 3  106 virus copies/ml in those infected with
delta nef virus-infected cells (Fig. 3A). On average, the plasma
virus levels of animals infected with delta nef virus-pulsed DCs
or T cells then decreased to significantly lower set point levels
(six of them often had 1,500 copies, and one had 105
copies, which later dropped to 4  103 copies) than those
seen with wild-type infections (persisting at between 105 and
109 copies). One exception among the delta nef virus-infected
animals (animal P318) did develop an anti-SIV Ab response
(Table 2), but its plasma virus load diminished only about 1 log
unit after the peak level and remained at around 2  105 to 5 
105 copies/ml over the next weeks (Fig. 3A).
Similarly, s.c. injection of cell-free SIV resulted in peak
infections within 2 to 3 weeks in three of the four animals (Fig.
3A). All three of these animals exhibited peak virus loads of
between 107 and 108 copies and maintained high set point
values of around 106 to 107 copies; this was so even in AR 73,
an animal injected with 105 TCID50 of delta nef virus. There
appeared to be little difference between animals receiving 102
or 105 TCID50 of wild-type virus, with both also exhibiting high
SIV Ag levels and anti-SIV Ab responses in the plasma (Table
2). Interestingly, the dramatic (possibly misleading) infection
of AR 73 with nef-defective virus may be attributed to the fact
that this animal appeared to be a rapid progressor, never
developing detectable anti-SIV Ab responses (Table 2), even
at necropsy. In contrast, animal N992, infected with the low
dose of delta nef virus, spiked with only low-level viremia of up
to105 copies per ml after 6 weeks, with virus remaining unde-
tectable for much of the time during this period.
As expected, the i.v. infected animals that were included as
additional internal controls for the wild-type and delta nef
infections exhibited peak virus loads within 2 weeks which
dropped to the various set point levels thereafter (Fig. 3B) and
had infectious virus detectable within 5 days of infection in
their PBMCs and LNCs; PBMC samples from all animals were
SIV gag PCR positive. However, one wild-type virus-infected
animal (AT 88) developed rapidly progressing immunodefi-
ciency syndrome with sustained high plasma viremia. AT 88
died from simian AIDS at week 12 without developing a de-
tectable Ab response to SIV. One animal, AR 85, that received
delta nef virus had approximately 1-log-unit-higher virus levels
than the other delta nef virus-infected animals and did not
show as rapid a decrease in viremia after the initial peak at 2
weeks. Interestingly, while the other delta nef virus-infected
TABLE 2. Transmission of infection by injected cell-free or
cell-associated wild-type and nef-defective SIVmac239





G544 3  105 wt-DCs   13 mo
AR 82 3  105 wt-DCs   19 wk
H917 3  105 wt-DCs   8 mo
H522 1.2  106 wt-DCs  NDe 3 mo
I686d 9  105 wt-DCs  ND 3 mo
M846 3  105 delta-DCs   17 mo
K080 3  105 delta-DCs   27 mo
P741 3  105 delta-DCs   37 mo
P318 3  105 delta-DCs   28 mo
AT 53 1.2  106 delta-DCs  ND 3 mo
C577 1.2  106 delta-DCs  ND 3 mo
L721 3  105 wt-T cells   15 mo
L702 3  105 wt-T cells   6 mo
J696 1.2  106 wt-T cells  ND 3 mo
J995 1.2  106 wt-T cells  ND 3 mo
M177 3  105 delta-T cells   24 mo
L507 3  105 delta-T cells   Alive 3 yr
AR 73 1  105 delta, s.c.   3 mo
N992 1  102 delta, s.c.   Alive 3 yr
M806 1  105 wt, s.c.   13 mo
AR 79 1  102 wt, s.c.   4.5 mo
AR 70 1  105 wt, s.c.   3 mo
G402 1  105 wt, s.c.   7 mo
AT 88 1  102 wt, i.v. ND  11 wk
AR 80 1  102 wt, i.v. ND  19 mo
AT 62 2.35  104 delta, i.v. ND  Alive 3.5 yr
AT 84 2.35  104 delta, i.v. ND  19 mo
AR 83 2.35  104 delta, i.v. ND  Alive 3.5 yr
AR 85 2.35  104 delta, i.v. ND  13 mo
a wt-DCs, wild-type virus-infected DCs; delta-DCs; delta nef virus-infected
DCs.
b Plasma p27 Ag was detected within 1 to 3 weeks of infection, and anti-SIV
envelope Abs we detected by weeks 8 to 12 p.i., varying as expected between
donors. Positivity was confirmed in at least one follow-up measurement, and
negative results reflect animals that never seroconverted during that testing
period.
c Animals were euthanized if they appeared to be ailing, and necropsy samples
were analyzed where possible. H522, I686, AT 53, C577, J696, and J995 were
euthanized and necropsied after 3 months.
d I686 received only 3  105 cells at three sites. Note that the i.v. delta nef
virus-infected animals AT 62, AT 84, AR 83, and AR85 were i.v. challenged with
100 TCID50 of wild-type virus 15 weeks after their initial infection with delta nef
virus for use in other ongoing immune studies. In other continuing studies,
animals M846, K080, P318, P741, M177, L507, and N992 were similarly i.v.
challenged with wild-type virus approximately 11 months after injection of cell-
associated or cell-free delta nef virus. All times of death are relative to the initial
infection with delta nef virus.
e ND, not done.
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animals remained healthy, AR 85 developed immunodeficien-
cies and died at 59 weeks after infection.
Thus, both cell-free and cell-associated wild-type as well as
delta nef SIV are infectious when administered s.c., and the
latter infection can be achieved with as few as 3  105 virus-
carrying DCs or T cells. Moreover, cell-borne delta nef virus
results in a similarly attenuated acute viremia as seen in i.v.
infection with cell-free virus.
Increased involvement of infected macrophages following
cell-associated virus transmission. Both DCs and T cells are
able to transmit infection of either delta nef or wild-type SIV
upon s.c. injection (Fig. 2 and 3; Table 2). We were interested
to ascertain how each infectious source is amplified during
acute infection. CD4 T cells have previously been shown to
be the major source of virus after infection with cell-free wild-
type SIV (47, 52) or delta nef SIV (46) applied to the mucosal
surfaces, but is the initial focus of infection distinct if the virus
is delivered in a cell-bound or cell-free form?
To address this question, ISH and IH were performed on the
frozen LN samples collected during the first 14 days of infec-
tion. Irrespective of the infectious inoculum, only after 14 days
were there sufficient numbers of SIV-positive cells in the tis-
sues to be phenotyped (Tables 3 and 4). CD3 T cells were
characterized by staining of small cells for CD4. DC subsets
were identified by the expression of CD1a for the LC-like DCs
(26) or DC-LAMP (CD208), which is a lysosome-associated
membrane protein expressed by activated DCs (9). An Ab
against the lysosomal marker CD68 was used to mark macro-
phages (36). Although they may be hard to detect in vivo, DCs
can also express CD68 (33). Therefore, macrophages were
more carefully defined by using an Ab against sialoadhesin
(CD169), a lectin with Ig superfamily domains that binds sialic
acid and is expressed exclusively by a subset of macrophages
(30, 35). CD169 is not expressed by macaque skin- or mono-
cyte-derived DCs (unpublished observations). Large CD4
cells remain unidentified, as they may represent activated T
cells, macrophages, or possibly even DCs.
A summary of the ISH data obtained for the control i.v.
infected animals at 14 days p.i. is provided in Table 3. The
distribution of virus-positive cells was predominantly within
the T-cell areas of the LNs, with very little (if any) trapping of
virions (immune complexed) in the germinal centers being
detected at this early stage. While very few virus-positive cells
were detectable before day 14, considerably higher (at least 10
times greater) numbers of SIV ISH-positive profiles were de-
tected in wild-type virus-infected animals. Only AR 85, the
delta nef virus-infected animal with plasma virus levels com-
parable to those of the wild-type virus-infected animals (Fig.
3), showed similar numbers of ISH-positive cells (Table 3).
Much like as seen after cell-free infection via the mucosa (47,
52), combined ISH and IH analysis of the tissues confirmed
that CD4 T cells were the main source of virus production in
both the wild-type (Fig. 4, animal AT 88) and delta nef virus-
infected animals. No CD169 cells (Fig. 4, animal AR 80) and
rarely any CD68 cells (Fig. 4, animal AT 88) were found to be
SIV positive. Therefore, while there were considerably fewer
virus-producing cells detected in the LNs after i.v. infection
with the attenuated delta nef compared to the wild-type virus,
CD4 T cells (and not macrophages or DCs) were the main
source of virus production in each case.
Similarly, we detected the heaviest infections in the T-cell
areas of the day 14 LNs of animals s.c. injected with either
cell-free or cell-associated virus (Table 4). Although punch
biopsies were taken of each injection site on days 1, 3, 7, and
14 p.i. (coincident with the LN biopsies), we were unable to
detect any virus-producing cells indicative of virus expansion
directly at the injection sites. In the LNs virus-positive cells
were rare before day 7 p.i. Again, considerably fewer virus-
positive cells were apparent in animals receiving delta nef vi-
rus-pulsed DCs (Table 4). The higher plasma viral loads in the
wild-type- compared to the delta nef virus-infected monkeys
generally correlated with many fewer ISH-positive cells in the
lymphoid tissues of the latter. Unfortunately, due to the lim-
ited numbers of SIV RNA-positive cells in the frozen tissues
from the delta nef virus-infected animals (Table 4), we were
unable to confidently identify the virus-positive cells in these
tissues.
As observed after i.v. infection with cell-free virus, CD4
cells were the major source of virus production in the tissues
from animals s.c. infected with cell-free wild-type SIV (Fig. 4,
FIG. 2. PCR confirmation of infection via DC-associated and cell-
free s.c. administered virus. (A) Immature DCs from two healthy
macaques (P741 and H917) were exposed to 0.1 MOI of delta nef
(P741) or wild-type (H917) SIV and washed, and an aliquot (of the
cells injected into the animals [Fig. 3]) was cultured alone (DC) or with
174xCEM cells (DCCEM) for 2 days (at a DC/174xCEM ratio of
1:10). After culture, the cells were collected and the SIV gag DNA
levels evaluated by PCR. The standard curve of controls described for
Fig. 1 is included. (B) PBMCs were prepared from blood samples
taken 1, 4, and 6 weeks after injection of animals with delta nef virus-
infected DCs (K080 and M846), wild-type virus-infected DCs (AR 82
and G544), or cell-free wild-type virus (M806) (Table 2). SIV gag DNA
levels were detected by PCR analysis, confirming the presence of in-
fection in all animals compared to the standard curve controls (Fig. 1).
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animal AR 70). There were no SIV-positive CD1a or
CD208 DCs detected and very few (1 to 10%) SIV-positive,
CD169 macrophages (Fig. 4, AR 70 and G402). The numbers
of SIV-positive cells and what percentages of these are
CD169 macrophages are summarized in Table 4. In striking
contrast, the LNs of animals infected with cell-associated wild-
type SIV included SIV-positive CD4 T cells (Fig. 4, animal
I686) and significant numbers of SIV-positive macrophages
identified by using both CD169 and CD68 staining (Fig. 4,
animals I686 and J995). As many as 25 to 50% of the SIV
RNA-positive cells were CD169 macrophages (Table 4).
Some large CD4 cells that may be activated T cells, macro-
phages, or DCs were detected (Fig. 4, animal I686). The pos-
sibility that the large CD4 cells are DCs seems unlikely, since
we observed no SIV-positive CD208 or CD1a cells (Fig. 4,
animals I686 and J995), also decreasing the likelihood that the
SIV-positive CD68 cells may include immature DCs. This
was independent of the cell type that introduced the infectious
virus. Figure 4 represents an overview highlighting the in-
creased frequency of infected CD169 macrophages in ani-
mals receiving cell-associated virus. Without performing three-
or four-color confocal microscopy on thin sections to defini-
tively identify the virus-positive cells (25), we cannot exclude
the possibility that the CD169 SIV-positive cells may repre-
sent SIV-positive T cells clustered closely to CD169 macro-
FIG. 3. Transmission of infection by cell-associated versus cell-free
virus. (A) Immature monocyte-derived DCs or CD4 T cells were
isolated from 17 healthy macaques (as indicated) and exposed to an
MOI of 0.1 of SIVmac239 wild-type or SIVmac239 delta nef virus.
After an overnight incubation, the cells were collected, washed, and
recounted, and 3  105 to 1.2  106 SIV-bearing DCs or T cells were
reinjected into the donor animals proximal to the inguinal or axillary
LNs (Table 2). Individual animal numbers are listed in each graph.
Four other animals were s.c. injected with the indicated doses of
cell-free virus. (B) Six healthy macaques were infected i.v. with either
102 TCID50 of wild-type SIVmac239 or 2.35  10
4 TCID50 of delta nef
SIVmac239. Plasma viremia was measured by bDNA analysis for up to
100 days after injection of cell-associated or cell-free virus to reveal the
number of SIV RNA copies per milliliter of plasma.
TABLE 3. SIV RNA expression in the LNs of i.v. infected
macaques at 14 days p.i.




AT 88 1  102, wt 348.5 52
AR 80 1  102, wt 234.5 16.1
AT 62 2.35  104, delta 17.25 3.15
AT 84 2.35  104, delta 8.2 0.4
AR 83 2.35  104, delta 15 0.72
AR 85 2.35  104, delta 132 6.5
a wt, wild-type virus; delta, delta nef virus.
b Average numbers of RNA-positive cells (by ISH) at day 14. LNs were
biopsied at days 2, 5, 7, and 14. However, negligible numbers of SIV-positive cells
were detected before day 14 (ranging from 0.08 to 2.25 SIV-positive cells per
mm2 or 0.5 to 38 SIV-positive cells per section at day 7).
TABLE 4. Increased numbers of CD169-positive, SIV
RNA-expressing cells in LNs 14 days after s.c.
reinjection of cell-associated virus
Animal Inoculum(s.c.)c
No. of RNA-
positive cells pera: % of RNA-positive cells
expressing CD169b
Section mm2
I686 wt-DCs 890 24.18 49.36
H522 wt-DCs 853 29 25.61
C577 delta-DCs 135 10.5 NDd
AT 53 delta-DCs 20 0.9 ND
J696 wt-T cells 1,495 48.14 28.78
J995 wt-T cells 1,758 29.42 50.52
AR 70 105 TCID50 wt 185 6.16 9.5
G402 105 TCID50 wt 147 16.4 1.5
a LNs were biopsied at days 1, 3, 7, and 14 after injection of cell-associated
virus and 14 days after infection with cell-free virus. As with the i.v. infected
animals, few SIV-positive cells were detected before day 14 (i.e., at day 7 the
numbers of SIV-positive cells ranged from 0.0 to 2.4 per mm2 or 0 to 36 per
section).
b CD169 stains were performed on day 14 samples where sufficient RNA-
positive profiles were available to phenotype.
c Animals were s.c. injected with DC- or T-cell-associated wild-type (wt) or
delta nef (delta) virus or with 105 TCID50 of cell-free wild-type virus.
d ND, not done, as there were too few RNA-positive cells.
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phages. However, this seems unlikely due to the significant
differences between the animals exposed to virus in the cell-
free versus cell-associated forms, as one would expect that such
observations would be made in tissues from both groups of
animals. Therefore, unlike what is seen with when cell-free
virus is administered via the i.v. or s.c. (see above) or mucosal
(46) routes, s.c. injected cell-borne virus appears to result in
increased infection of macrophages in addition to the T cells
during the early stages of infection.
DISCUSSION
Both DCs and T cells can transmit SIV and HIV in vitro (13,
22) and likely drive the early stages of virus spread following
mucosal exposure (16, 46, 47, 52). However, little is known
about their potential to introduce virus and initiate infections
in vivo. The present study provides direct evidence for the
ability of DCs and T cells to efficiently transmit wild-type and
nef-defective SIVmac239 after being pulsed with relatively
small amounts of virus ex vivo. As expected from the i.v. in-
fections (see, e.g., Fig. 3B and Table 3), wild-type virus intro-
duced s.c. in either the cell-free or cell-associated form re-
sulted in more robust virus infection and heavier virus loads
than in delta nef virus-infected animals (Fig. 3A and Table 4).
The need for nef to drive virus replication in the immature
DC–T-cell milieu (34, 38) is probably being manifest here
following s.c. delivery of virus into a similar cellular locale. Just
as we observed in vitro (34), this occurs irrespective of whether
the virus is added to the local milieu as free virus or is intro-
duced by either immature DCs or CD4 T cells. Of note,
although the levels of virus replication were lower in animals
receiving delta nef virus-pulsed cells, this virus did replicate to
greater extents than we saw in our in vitro assay (34) and did
not require the almost 250-times-more virus often used for
cell-free i.v. infection.
In vitro, very little replication of the attenuated virus oc-
curred in immature DC–T-cell mixtures, in contrast to that in
the presence of mature DCs or if the immature DCs intro-
duced the same amounts of wild-type virus (34). The differ-
ences between the levels of delta nef virus replication in vitro
and in vivo could be due to possible maturation of the delta nef
virus-bearing immature DCs after s.c. injection (4). The ma-
tured DCs could thereby overcome the need for nef for effi-
cient viral replication as seen in vitro. However, while it could
be different in vivo, the fact that activation or maturation of
delta nef virus-carrying immature DCs in vitro did not result in
enhancement of delta nef virus replication argues against this
possibility (D. Messmer et al., submitted for publication). In
contrast, activation of the T cells in such cultures readily res-
cued delta nef virus replication. Therefore, it is possible that in
vivo there is at least low-level T-cell activation (not necessarily
virus specific) that could facilitate greater amplification of im-
mature DC-borne delta nef virus. Furthermore, should the
virus-carrying immature DCs meet memory CD4 T cells, such
as those positioned at the body surfaces, this would only exac-
erbate virus spread, as observed in vitro (13) and in vivo (49,
50).
The transmission of infection by ex vivo virus-loaded DCs or
T cells probably involves virus that has infected the cells as well
as virus that is simply bound on the cell surface and/or trapped
within intracellular compartments (12, 15, 37). T cells capture
immunodeficiency viruses primarily via CD4 and chemokine
coreceptors, while DCs can capture viruses via CD4, chemo-
kine coreceptors, and members of the C-type lectin receptor
family (13). The variable expression of these molecules by
different DC subsets as well as by DCs at different stages of
activation makes it likely that virus will utilize different recep-
tors depending on the DC subset it meets and the route of
transmission. Irrespective of the cell-cell interactions driving
infection, this is the first study showing significant viral repli-
cation in non-T cells at an early stage of infection specifically
following transmission of cell-associated virus. Previous studies
utilizing cell-free virus applied to the mucosae highlight how
DCs can capture and possibly replicate virus early (16) but that
CD4 T cells take over to further amplify virus levels (46, 47,
52). Comparably, in the present study, cell-free virus injected
either i.v. or s.c. replicated predominantly in the CD4 T-cell
compartment, and infected macrophages probably contributed
little to the infection (Table 4 and Fig. 4). In striking contrast,
when virus was administered in CD4 T-cell- or DC-associated
forms, early virus replication was detected in both macro-
phages and CD4 T cells. This shift in virus-producing cells to
include up to 50% of CD169 macrophages occurred with
T-cell- or DC-borne virus. Virus-positive DCs could not be
detected in significant numbers, suggesting that DCs favor
transferring the virus to more permissive cell types while po-
tentially providing signals (especially to resting T cells) to drive
virus growth.
The mechanism for the enhanced macrophage tropism of
wild-type SIV after inoculation in cell-bound form is under
investigation. Recently, Igarashi et al. (19) reported that high
numbers of infected macrophages could be detected only after
the depletion of CD4 T cells as a result of infection with the
highly pathogenic SHIVDH12R. In our study, however, the LNs
of animals inoculated with cell-bound virus did not reveal any
FIG. 4. Increased numbers of virus-infected macrophages in the LNs of animals receiving cell-associated virus. Combined ISH and IH data for
the draining LNs of six representative animals, biopsied 14 days after injection of cell-associated versus cell-free SIV, are shown. Animal I686
received wild-type virus (wt)-infected DCs, J995 received wild-type virus-infected T cells, AR 70 and G402 were injected with cell-free wild-type
virus, and AR 80 and AT 88 were i.v. infected with wild-type virus. Frozen tissues were processed for IH against the indicated markers (red),
counterstained with hemalaun (purple-blue), and followed by ISH for SIV RNA (black grains). Small CD4 T cells (arrows, I686), large CD4
cells (macrophages or activated T cells; asterisks, I686), and CD169 and CD68 macrophages (arrowheads, I686 and J995) that are positive for
SIV are apparent in animals injected with either DC- or T-cell-associated SIV. SIV-positive cells are negative for the DC markers CD208 (I686
and J995) and CD1a (J995). The SIV-positive cells in AR 70 and G402 lacked CD169 but expressed CD4 (asterisk). The CD4 cell expressing
SIV in the example shown for AR 70 appears to be intermediate in size and is thus difficult to definitively identify as either a T cell or macrophage.
SIV-positive cells in the cell-free SIV-infected i.v. controls (AR 80 and AT 88) are smaller CD4 cells (arrow) with few CD68 cells (arrowhead)
that lack CD169. Magnifications, 40 (CD1a and CD208 panels of J995) and 100 (all other panels).
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major loss of CD4 T cells that might identify a similar phe-
nomenon. The fact that cell-free SIVmac239 replicated pre-
dominantly in CD4 T cells while cell-associated SIVmac239
grew in both macrophages and T cells implies that it is the form
of introducing the virus that determined the fate of the virus in
this setting. It is possible that the s.c. injection of cell-borne
SIV caused the secretion of chemokines and/or proinflamma-
tory cytokines that lead to the recruitment of macrophages
(and possibly T cells) and perhaps a minor inflammation at the
site of injection. In this situation, the infected cells could sim-
ply hand over the virus to the attracted cells, which subse-
quently could migrate to the draining LNs and there amplify
infection in concert with CD4 T cells. On the other hand,
although DCs not carrying SIV readily migrate to the draining
LNs (reference 4 and unpublished observations) some (or all)
of the injected virally infected cells could die at the site of
injection or after having migrated to the draining LNs, and the
resulting cellular debris could be picked up by macrophages or
resident DCs. Both macrophages and DCs can pick up the
remainder of apoptotic or necrotic cells via receptor-mediated
endocytosis (1, 2). A recent report revealed that uptake of
apoptotic debris augments HIV infection of macrophages in
vitro (29), supporting the notion that a similar mechanism may
contribute to enhanced macrophage infection in vivo. In the
LNs, virus-laden macrophages could directly foster virus growth,
while DCs carrying virus could transmit infection to neighboring
CD4 T cells. It is of course possible that the injected virus-
carrying cells migrated directly to the draining LNs, where they
interacted with the cellular milieu to augment virus growth.
This further supports the idea of cell-cell communication need-
ed for viral amplification, much as is observed in cocultures of
infected DCs and T cells (13, 22). In vitro studies are under way
to dissect the events dictating cell-cell transmission of virus.
Due to low numbers of SIV-positive cells in the tissues even
after 14 days after delta nef virus infection (Table 4) we were
unable to phenotype the cells that were the initial focus of virus
replication in these settings. Thus, we still need to ascertain if
there are differences between the cells fostering virus growth
after cell-associated wild-type versus delta nef virus infection.
However, recent studies applying cell-free delta nef virus to the
mucosa (46) resulted in T-cell infection similar to that seen
with wild-type virus (47). In addition, we cannot say whether
the same profiles would apply to the most acute stages of
infection or whether DCs may contribute at these earlier time
points before virus is transmitted and exacerbated in the more
permissive CD4 T cells and macrophages.
This study provides the first report that SIV infection can
readily be transmitted with virus carried by defined cell types,
i.e., CD4 T cells and DCs. By investigating the sites of early
viral replication, we have revealed significant differences in the
cells forging virus growth in a setting mimicking cell-bound
versus cell-free virus that has breached the body surface. The
pronounced involvement of macrophages following cell-asso-
ciated infection might have considerable impact on the subse-
quent induction of immune responses and on the development
of strategies to prevent virus transmission.
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